Skip to content
GLP-1 Decoder

Wegovy for Type 2 Diabetes: Evidence, Eligibility, Coverage

Wegovy is not FDA approved for type 2 diabetes. It is approved for weight loss, heart risk and MASH liver disease. Ozempic and Rybelsus, with the same ingredient, are approved for type 2 diabetes. In STEP 2, people on Wegovy lost 9.6% of body weight on average, vs 3.4% on placebo.

For type 2 diabetes
Not an approved use
Active ingredient
semaglutide
How it is taken
weekly injection or daily tablet
Best result (STEP 2)
9.6% weight loss

Wegovy overview

How long the drug stays in your body
100%50%25%0%07 d14 d21 d28 d35 d50%25%12.5%time after the dose

Its half-life is about 1 week: after 7 d, half remains, and five half-lives (35 d) leave about 3%.

Weight loss in the main trial
Wegovy (STEP 1)14.9%Placebo2.4%

After 68 weeks, STEP 1 showed 14.9% of body weight, compared with 2.4% on placebo.

Costs over time
202520262027$1,349.02$0List priceSelf-pay

Monthly US dollar price points include the list price and self-pay offers. Each comes from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Wegovy: who qualifies
SourceWho qualifies
FDA labelHeart attack, stroke, or heart-related death becomes less likely in adults with heart disease who also have obesity or overweight (injection and tablets).
FDA labelFor adults and children 12 and older with obesity, this treatment supports sustained weight loss and maintaining that loss when used with diet and activity. It also applies to adults with overweight and a weight-related condition.
FDA labelIt treats MASH liver disease with moderate to advanced scarring but no cirrhosis in adults (injection).
FDA labelFor adults, the tablets are approved for weight loss and lowering heart risk.

Label source: FDA label (DailyMed) information.

Trial results for type 2 diabetes

Wegovy trials in type 2 diabetes
TrialMedicineWho took partLengthPeopleMain resultComparison
STEP 2 WegovyAdults with type 2 diabetes who have obesity or overweight68 weeks1,2109.6% weight loss3.4% on placebo

Trial sources: STEP 2 (PubMed).

What differs with type 2 diabetes?

Wegovy label information for type 2 diabetes
What changesWhat the label says
HypoglycemiaUsing it alongside insulin or a sulfonylurea raises the likelihood of low blood sugar. Doses of those drugs may need lowering.
Complications from Diabetic Retinopathy in People with Type 2 DiabetesWith type 2 diabetes, diabetic eye disease may worsen, particularly when blood sugar falls quickly. Eye checks matter if you already have it.
Taken with insulin or sulfonylureasTaking it with insulin or a sulfonylurea, such as glipizide or glimepiride, makes low blood sugar more likely. Your doctor may lower those doses.

Sources: FDA label (DailyMed) information.

Label warnings: FDA label on DailyMed.

Coverage for type 2 diabetes

Medicare Part D can cover these medicines if prescribed because of diabetes or cardiovascular disease.

Sources: humana.com.

Alternatives for type 2 diabetes

GLP-1 medicines and type 2 diabetes
MedicineFor type 2 diabetesHow it is takenTrial result
OzempicFDA approvedweekly injectionNot listed
RybelsusFDA approveddaily tabletNot listed
MounjaroFDA approvedweekly injectionA1C down 2.3 points
TrulicityFDA approvedweekly injectionA1C down 1.77 points
VictozaFDA approveddaily injectionNot listed
ByettaFDA approvedtwice-daily injectionNot listed
WegovyNot an approved useweekly injection or daily tablet9.6% weight loss
ZepboundNot an approved useweekly injection14.7% weight loss
FoundayoNot an approved usedaily tablet9.6% weight loss
SaxendaNot an approved usedaily injection7.4% weight loss

Sources: FDA label on DailyMed, PubMed.

Questions for your prescriber

Read all of the Wegovy prescribing information on DailyMed.